Specialty pharma player ANI Pharmaceuticals is pressing ahead with its strategy of building out its portfolio through acquisitions, partnerships and internal development. The niche generics-and-brands firm has just purchased a pipeline of seven development-stage generics from Coeptis Pharmaceuticals for $2.3m in cash and up to $12m in development and commercial milestone payments. Citing IQVIA data, ANI said the portfolio “has a combined (estimated) current annual US market value of $1.02bn.”
ANI Strikes Deal With Coeptis For Seven Development-Stage Assets
Continuing its acquisition streak, ANI Pharmaceuticals has bought a pipeline of seven development-stage generics from Coeptis Pharmaceuticals for $2.3m in cash and up to $12m in development and commercial milestone payments.
More from Deals
• By
Sandoz has struck a deal worth up to $301m with Henlius giving it rights to a proposed ipilimumab biosimilar to Yervoy in countries across the world.
• By
The move adds another compound with the coveted 180-day exclusivity to Hikma’s portfolio for an undisclosed sum.
• By
After announcing the agreement last month, Xbrane has now approved its deal with Alvotech as part of an extra general meeting.
• By
With six biosimilars reportedly in development, Polpharma Biologics has linked up with Chinese CDMO Chime Biologics, looking to tap its “all-in-one solutions to accelerate biosimilar development and reduce the time-to-market” for an undisclosed biosimilar product.
More from Business
• By
Generics Bulletin previews the most noteworthy and anticipated events for May 2025.
• By
Sandoz has struck a deal worth up to $301m with Henlius giving it rights to a proposed ipilimumab biosimilar to Yervoy in countries across the world.
• By
Reflecting increased regulatory pressure and a wider drive towards the reshoring of pharmaceutical manufacturing to the US, Speranza has launched a new generics business called Lotus Therapeutics.